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Abstract: Psoriasis is a chronic and immunomediated skin disease characterized by 
erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian 
population. Tumor necrosis factor alpha (TNF-α) is a proinﬂ  ammatory cytokine that plays a 
critical role in the pathogenesis of psoriasis. Inﬂ  iximab is an anti-TNF-α drug widely used 
for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials 
demonstrated that inﬂ  iximab is characterized by a high degree of clinical response in moderate 
to severe plaque psoriasis. Moreover inﬂ  iximab showed rapid efﬁ  cacy in nail psoriasis which 
represents a therapeutic challenge for dermatologists and a relevant source of distress for patients 
with plaque psoriasis. This anti-TNF-α has an encouraging safety proﬁ  le, especially as long as 
physicians are watchful in prevention and early diagnosis of infections and infuse reactions. 
The efﬁ  cacy, tolerability and safety proﬁ  les suggest inﬂ  iximab as a suitable anti-psoriatic drug 
in the long-term treatment of a chronic disease such as plaque-type psoriasis.
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Introduction
Psoriasis is a chronic and immunomediated skin disease characterized by erythema-
tous scaly plaques. Approximately 1% to 3% of the Caucasian population suffers 
from this disease.1 Psoriasis entails a psychological morbidity comparable to other 
major chronic diseases such as heart disease, cancer and diabetes.2 The most common 
clinical variant is plaque psoriasis, occurring in more than 80% of affected patients;3 
up to 40% of psoriatic patients develop an inﬂ  ammatory deforming arthritis termed 
psoriatic arthritis (PsA).4
Traditional treatments for patients with moderate to severe plaque psoriasis include 
ciclosporin, methotrexate, acitretin, ultraviolet B (UVB), and ultraviolet A with pso-
ralen (PUVA), both in monotherapy and combination. Ciclosporin is one of the most 
effective therapeutic options against psoriasis, even though long-term treatment is 
associated with hypertension and renal failure.5 Similarly, methotrexate can lead to 
liver toxicity and pancytopenia.6 Acitretin alone is only partially effective and rarely 
leads to a complete clearance of the skin lesions. Additionally, it produces substantial 
mucocutaneous toxic effects and, similarly to methotrexate, is teratogenic. UVB and 
PUVA both require an intensive treatment regimen (about 3 times per week prolonged 
for months), reducing patients’ compliance. Additionally, PUVA has been associated 
with skin cancers.7 The use of biological drugs can be seen as one of the greatest 
advances made in the treatment of psoriasis. These drugs have a selective action on 
receptors and mediators such as tumor necrosis factor alpha (TNF-α) which plays a 
key role in psoriasis.
Pathogenesis and TNF-α
Both adaptive and innate immunity are involved in the pathogenesis of psoriasis. The 
disease is characterized by an abnormal skin proliferation due to complex interactions 
between immune cells and keratinocytes (KCs).1 Psoriatic plaques are characterized by Clinical, Cosmetic and Investigational Dermatology 2009:2 28
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an increased skin-homing activated T cells rate, expressing 
both lymphocyte function-associated antigen-1 (LFA-1) and 
cutaneous lymphocyte antigen (CLA);8,9 CD4+ T helper-1 
(Th1) cells, the newly described Th17 cells, and dermal 
CD11+ dendritic cells (DCs) down-regulate epidermal dif-
ferentiation genes, leading to abnormal KC proliferation 
and parakeratosis.10 The disease development depends on a 
mixed Th1/Th17 immune response inducing dermal DCs and 
macrophages to express mediators that favor inﬂ  ammation 
and excessive KC proliferation, such as TNF-α and inducible 
nitric oxide synthase (iNOS).10
Several inﬂ  ammatory mediators are overexpressed in 
psoriatic lesions, but only some of these have been shown 
to be of primary importance to the disease pathogenesis.11 
Among the cytokines whose levels are increased in psoriatic 
plaques, TNF-α seems to play a major role in this process; 
TNF-α, via activation of nuclear factor-κB (NF-κB), promotes 
the synthesis of numerous cytokines and chemokines such as 
IL-8 and IL-6.12 In addition, TNF-α potentially contributes 
to the recruitment and accumulation of inﬂ  ammatory cells, 
which are observed in both epidermis and dermis, by inducing 
the expression of intercellular adhesion molecule-1 (ICAM-1) 
on the surface of endothelial cells (ECs) and KCs. Of note, 
TNF-α upregulates ICAM-1 expression on the endothelial 
surface of microvessels, even though expression patterns 
differ between arterioles and venules. In venules, TNF-α 
leads to a further upregulation of ICAM-1 expression in the 
ECs already showing substantial ICAM-1 levels on their 
surface under normal conditions; by contrast, in arterioles 
the TNF-α-mediated endothelial upregulation of ICAM-1 
correlates with a spatial variation of the ICAM-1 expression 
pattern among ECs. The TNF-α-dependent increase in the 
ICAM-1 endothelial expression produces quantitative and 
spatial variations in leukocyte-EC adhesion interactions in 
venules and leukocyte-EC rolling interactions in arterioles. 
These ﬁ  ndings suggest that arterioles have an important role 
in the inﬂ  ammatory cascade and that the spatial distribution 
as well as the expression levels of adhesion molecules in 
the microcirculation inﬂ  uence the timing and placement 
of leukocyte interactions and hence signiﬁ  cantly affect the 
inﬂ  ammatory response.13
Langerhans cells represent one of the main antigen 
presenting cells of the skin, inducing the activation of 
T cells. TNF-α is known to stimulate the migration of Lang-
erhans cells to lymph nodes and to enhance the capability 
of presenting antigen to primed T cells.14 TNF-α activity 
blockade results in a noticeable reduction in inﬂ  ammation, 
keratinocyte proliferation and differentiation abnormalities 
in psoriasis. Effective treatment with TNF-blocking drugs 
rapidly down-modulates inﬂ  ammatory dermal DC products 
TNF-α, iNOS, IL-20 and IL-23.15
Inﬂ  iximab
Inﬂ  iximab (Remicade®; Centocor, Inc.) is a recombinant 
immunoglobulin IgG1 chimeric antibody composed of human 
constant and murine variable regions that speciﬁ  cally binds 
to and blocks both trans-membrane and soluble TNF-α, but 
not lymphotoxin α (TNF-β). In vivo, inﬂ  iximab quickly 
forms stable compounds with human TNF-α, a process that 
leads to the loss of the biological activity of TNF-α.16 The 
binding between inﬂ  iximab and TNF-α has a high afﬁ  nity 
(K = 4.5 × 10−10M) leading to a temporary steric rearrange-
ment of TNF-α when it is bound to inﬂ  iximab, inhibiting 
the TNF-α from being recognized by its own receptor on 
the cell surface. Pharmacodynamic studies have shown the 
high afﬁ  nity of inﬂ  iximab that binds about 100% of TNF-α 
molecules after infusion.16
TNF-α is active as a homotrimer, but it is also found 
bound as a monomer, dimer or trimer to the surface of 
TNF-α-producing cells. Inﬂ  iximab binds to all forms of 
soluble and membrane-bound TNF-α with high speciﬁ  city. 
The concept that inﬂ  iximab is also able to at least partially 
antagonize receptor-bound TNF-α is based on the high 
afﬁ  nity of inﬂ  iximab to TNF-α and on the documented 
high association-dissociation rate between TNF-α and TNF 
receptor.16,17 Inﬂ  iximab and TNF are multivalent proteins: in 
a situation of antigen excess, one of inﬂ  iximab molecules can 
bind two different TNF trimers, whereas in case of antibody 
excess, three inﬂ  iximab molecules can be bound to one TNF 
trimer. The high afﬁ  nity, by means of the formation of large 
immune complexes, signiﬁ  cantly reduces the chance of 
bioactive TNF dissociating from inﬂ  iximab. The ability of 
inﬂ  iximab to bind membrane-bound TNF-α in this fashion 
appears to be of central importance to explain the additional 
effects on TNF-α–producing cells (apoptosis, complement 
lysis, antibody-dependent cellular cytotoxicity), which have 
been described in vitro and in vivo and have been proposed 
to play a major role in enhancing the clinical efﬁ  cacy of 
infliximab.17,18 Infliximab might lead to the deletion of 
immune cells expressing TNF-α on their surface, such as 
macrophages/dermal DCs and T cells.15
Inﬂ  iximab has been successfully used in psoriasis and in 
several off-label indications, such as hidradenitis suppurativa, 
pityriasis rubra pilaris and pyoderma gangrenosum among 
others.19,20 This anti-TNF-α drug was developed for the treat-
ment of various chronic inﬂ  ammatory disorders mediated Clinical, Cosmetic and Investigational Dermatology 2009:2 29
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by TNF-α and is approved for ulcerative colitis, adult and 
pediatric Crohn’s disease, rheumatoid arthritis (RA), and 
ankylosing spondylitis.
Inﬂ  iximab is administered as a short intravenous infusion 
over at least 2 hours at a total dose of 5 mg/kg body weight. 
According to the label for plaque psoriasis, infusions are 
given at weeks 0, 2, and 6 at the beginning (induction period) 
and then every 8 weeks for maintenance therapy. A single 
infusion of inﬂ  iximab leads to a mean maximum serum 
concentration (Cmax) of 118 μg/mL. The mean elimination 
half-life is approximately 8.5 to 9 days; however, depending 
on the dose and the duration of treatment, inﬂ  iximab can be 
detected in the serum for up to 28 weeks.21
Clinical efﬁ  cacy
Inﬂ  iximab was tested in several clinical trials involving 
patients suffering from moderate-to-severe psoriasis, at 
variable doses of 3, 5 and 10 mg/kg of body weight;22–24 
in these studies infliximab treatment was shown to be 
generally well tolerated and resulted in a rapid and signiﬁ  cant 
improvement in psoriatic signs and symptoms from baseline. 
Inclusion and exclusion criteria adopted in these phase II 
and III clinical trials were similar. Common inclusion 
criteria were: age   18 years, moderate-to-severe plaque-
type psoriasis for at least 6 months, ineligibility or disease 
unresponsive to current conventional systemic treatments. 
Main exclusion criteria were: history of opportunistic or 
chronic/recurrent severe infections, internal malignancies 
or severe infectious diseases detected within 3 months prior 
to the start of inﬂ  iximab treatment, drug-induced psoriasis, 
live vaccinations, clinically signiﬁ  cant abnormal laboratory 
values, previous treatment with biological agents, systemic 
lupus erythematosus, demyelinating diseases, severe con-
gestive heart failure, and non-cutaneous malignancies or 
lymphoproliferative diseases within the previous 5 years.
Patients had to be negative for latent tuberculosis, after 
speciﬁ  c screening including history, physical examination and 
puriﬁ  ed protein derivative (PPD) skin testing; with the exception 
of non-medicated emollients and salicylic or tar shampoos, 
during the entire duration of the clinical trials patients were not 
allowed to apply any other treatment for psoriasis. Conventional 
systemic therapies were to be interrupted at least 4 weeks before 
the ﬁ  rst infusion of inﬂ  iximab, whereas topical treatments could 
be continued until 2 weeks before this time.
The overall efficacy of infliximab treatment was 
commonly assessed by the percentage of patients who 
achieved at least 50% and 75% improvement in Psoriasis 
Area and Severity Index (PASI) score (PASI 50 and 
PASI 75 respectively), the physician global assessment 
(PGA) and/or the body surface area score (BSA).
Phase II studies evaluated the safety and efﬁ  cacy of 
inﬂ  iximab in plaque psoriasis at different dosage regimens. In 
the phase II study,22 2 doses of inﬂ  iximab (5 and 10 mg/kg), 
administered under a 3-dose induction regimen, were 
compared with placebo in 33 patients. Patients treated with 
inﬂ  iximab showed a higher and more rapid degree of clinical 
improvement, as measured by PGA and PASI score, than 
patients receiving placebo; at week 10, PASI 75 was achieved 
by 82% and 73% of patients who received 5 and 10 mg/kg of 
inﬂ  iximab, respectively, whereas such a result was observed 
in only 18% of patients treated with placebo (inﬂ  iximab 
5 mg/kg vs placebo p = 0.0089; inﬂ  iximab 10 mg/kg vs 
placebo, p = 0.03). The end point of “excellent” or ”clear” on 
PGA rating was achieved by 82% and 91% of patients in the 
inﬂ  iximab 5 and 10 mg/kg groups, respectively, by contrast 
with 18% of patients in the placebo group (inﬂ  iximab 5 mg/kg 
vs placebo, p = 0.0089; inﬂ  iximab 10 mg/kg vs placebo 
73%, p = 0.0019). Remarkably, patients receiving inﬂ  iximab 
showed signiﬁ  cantly higher mean percentage improvements 
in PASI score as early as week 2 (p   0.0003), and their 
median time to response was 4 weeks. In relation to efﬁ  cacy, 
there was no clinically signiﬁ  cant difference between 5 and 
10 mg/kg inﬂ  iximab regimen, while according to the safety 
proﬁ  le the 5 mg/kg regimen appeared to be preferable.
In the second phase II study,23 the above-mentioned 
3-dose induction regimen was further evaluated comparing 
3 mg/kg with 5 mg/kg inﬂ  iximab dose. This multicenter, 
double-blind, placebo-controlled trial was designed to 
assess the safety and efﬁ  cacy of inﬂ  iximab in 249 plaque 
psoriasis patients, presenting with BSA greater than 10%, 
in comparison with placebo; another aim of the trial was 
to test whether inﬂ  iximab could safely be readministered 
to patients 20 weeks after completion of the induction 
regimen. Eighty percent of patients treated with inﬂ  iximab, 
either 3 or 5 mg/kg, completed the 30-week study period, 
while this result was achieved by only 31% of the placebo-
group patients. A rapid onset of response to the inﬂ  iximab 
administration was observed in this trial, with a total of 34% 
of patients in the 3 mg/kg group and 40% of patients in the 
5 mg/kg group achieving PASI 50 at week 2 versus only 4% 
of the placebo-treated patients (p   0.001).
For both the inﬂ  iximab groups, the maximum response 
was observed at week 10, when 72% and 88% of patients 
receiving 3 and 5 mg/kg inﬂ  iximab, respectively, achieved 
PASI 75 score, compared with only 6% of patients in the 
placebo-group (p   0.001). The high degree of response Clinical, Cosmetic and Investigational Dermatology 2009:2 30
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began to decline in the 3 mg/kg group as early as week 10, 
whereas in the 5 mg/kg group it persisted until week 14. 
Five mg/kg of inﬂ  iximab was proved to be the ideal dose, 
as showed by the higher percentage of patients achieving 
PASI 75 at the end of the induction regimen.
The Evaluation of Inﬂ  iximab for Psoriasis Efﬁ  cacy and 
Safety Study (EXPRESS) was a Phase III, multi-center, 
double-blind, placebo-controlled trial evaluating the long-
term safety and efﬁ  cacy of inﬂ  iximab in the treatment of 
skin and nail disease in patients with moderate-to-severe 
psoriasis (BSA   10%, PASI   12%);24 378 patients were 
enrolled in a 4:1 ratio to receive either inﬂ  iximab 5 mg/kg or 
placebo; 301 patients were allocated to inﬂ  iximab 5 mg/kg 
and 77 to placebo. The inﬂ  iximab group received intravenous 
infusions of inﬂ  iximab 5 mg/kg at weeks 0, 2, 6 and every 
8 weeks until week 46. The placebo patients were infused 
at weeks 0, 2, 6, 14 and 22, crossing over in a double-blind 
manner to inﬂ  iximab 5 mg/kg at weeks 24, 26, 30 and every 
8 weeks up to week 46.
By week 6, PASI 75 response was achieved by approxi-
mately two-thirds of patients receiving infliximab and 
PASI 90 response was achieved by approximately one third. 
At the end of the induction period (week 10), the above-
mentioned goals were achieved by more than 75% and 
50% of inﬂ  iximab group patients, respectively, compared 
with less than 5% of the patients in the placebo group 
(p   0.0001). These data showed a continuous increasing 
in the response of patients rate during the induction period; 
at week 10, complete clearing of skin lesions was observed 
in approximately a quarter of inﬂ  iximab-treated patients. 
Also nail disease was proved to beneﬁ  t from inﬂ  iximab 
treatment (Figure 1).
By week 50, 61% and 45% of inﬂ  iximab-treated patients 
had achieved PASI 75 and 90 responses, respectively; the 
percentages of patients who had achieved PASI 50, 75 and 90 
were proved to be consistent with the degree of improvement 
shown at the end of the induction period (week 10).
The decline in PASI 75 at week 50 was not clinically 
signiﬁ  cant; nevertheless, it is important to investigate why 
some patients present a decrease in inﬂ  iximab-response from 
week 30 to 1 year. Possible explanations are high levels of 
serum inﬂ  iximab concentrations, changes in serum inﬂ  iximab 
concentrations or the presence of neutralizing antibodies. In 
fact, maintenance of response appeared to be related to both 
the level of serum inﬂ  iximab concentration achieved at week 
10 and the stability during treatment. In addition, mainte-
nance of clinical response was more commonly reported 
when antibodies to inﬂ  iximab were absent, although it must 
be emphasized that failure to respond to inﬂ  iximab was not 
fully reﬂ  ected by an antibody-positive status.
Therefore, in this study inﬂ  iximab was proved not only to 
be highly effective and rapid in the onset of action, but also 
to result in long-term remission of skin and nail lesions.
Inﬂ  iximab and other systemic 
anti-psoriatic treatments
Similarly to other biologics, inﬂ  iximab is currently recom-
mended by regulatory guidelines only as second-line therapy 
for patients complying with the following requirements: 
having failed to respond to conventional systemic agents 
and/or having become intolerant to conventional systemic 
therapy and/or being unable to receive conventional systemic 
therapy due to an increased risk of clinically relevant drug-
related toxicity.25,26 Nevertheless, there is a lack of evidence 
from “head-to-head” clinical trials comparing systemic 
biologic and non-biologic therapeutic options; however, 
two meta-analyses have been recently published, in which 
biologic drugs were compared alone and against non-biologic 
systemic treatments, respectively.27,28
Based on the PASI score and by a quantitative indirect 
analysis, Brimhall et al27 compared the efﬁ  cacy of alefacept, 
efalizumab, etanercept and inﬂ  iximab for moderate-to-severe 
plaque psoriasis. Efﬁ  cacy outcomes abstracted from this 
meta-analysis were 50%, 75% and 90% improvement in 
the PASI score (PASI 50, 75 and 90, respectively) at 10 to 
14 weeks of treatment. Indirect comparison of the efﬁ  cacy 
endpoints, all similarly compared with placebo, led to the 
following decreasing rank order of effectiveness: inﬂ  iximab, 
etanercept, efalizumab and alefacept. Nevertheless, caution 
must be exercised in interpreting these results because of 
the short duration of the analyzed studies, the different 
methodologies and administration (schedules and routes of 
admission) of the four different biological agents.
Schmitt et al28 took into account several randomized con-
trolled trials (RCTs) of both biologic and non-biologic systemic 
treatments approved for moderate-to-severe psoriasis. Simi-
larly to the previous meta-analysis, improvements in the PASI 
score were compared in order to determine the comparative 
efﬁ  cacy of these systemic drugs. In all the RTCs included 
in this meta-analysis, biologic and non-biologic treatments 
were administered at the recommended therapeutic dosage 
and compared with placebo or with other active treatments. 
Moderate-to-severe plaque psoriasis was deemed on the 
basis of a PASI cut-off of 7. The non-biologic systemic 
therapeutic options analyzed were ciclosporin (2.5–5 mg/kg), 
methotrexate (15 mg weekly), and fumaric acid esters.Clinical, Cosmetic and Investigational Dermatology 2009:2 31
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By contrast, biologic systemic agents studied by this 
meta-analysis were inﬂ  iximab (5 mg/kg), etanercept (both 
2 × 25 mg weekly and 2 × 50 mg weekly, respectively), 
efalizumab and adalimumab. The rate of patients with 
at least 75% reduction in PASI was the primary efﬁ  cacy 
outcome. Absolute risk differences (RDs) were adopted as 
effectiveness measure. The authors were not able to ﬁ  nd 
any head-to-head studies of different biologic treatments 
or of non-biologic agents; the time interval until assessing 
the primary efﬁ  cacy ranged between 8 and 16 weeks. The 
most efﬁ  cacious treatment found was inﬂ  iximab (RD 77%, 
95% CI 72%–81%), followed by adalimumab, which were 
signiﬁ  cantly more effective than all the remaining interven-
tions analyzed. These ﬁ  ndings support the conclusions of the 
previous meta-analysis. Nevertheless, in a subset patients 
initially responding to inﬂ  iximab a relapse in disease activity 
was recorded after 6 months of treatment, whereas etanercept 
was shown to be more reliable in inducing stable long-term 
response rates.
Based on the currently published data, among the TNF-α 
antagonists inﬂ  iximab appears to be the fastest drug inducing 
disease remission, with 80% of patients achieving PASI 75 at 
week 10 and a sustained response among the same patients 
at week 24. On the other hand, the clinical response with 
etanercept or adalimumab administration is characterized by 
a slower onset and a steady increase between weeks 12 and 
24, leading to an approximate rate of 50% of the etanercept-
treated patients and 64% of the adalimumab-treated patients 
reaching a PASI 75 response at week 24.
However, it should be emphasized once again that the 
clinical studies included in these meta-analyses are not 
head-to-head trials; thus they do not fulﬁ  ll the need for 
direct comparator trials and they must be conﬁ  rmed and 
strengthened by pragmatic head-to-head RCTs, lasting at 
least 2 years and comparing different biologic drugs both 
with each other and with conventional systemic treatments 
for psoriasis.
Safety, tolerability and management 
of infusion reactions
The overall safety proﬁ  le of inﬂ  iximab seems to be similar 
in all its indications. It cannot be excluded, however, that 
certain safety aspects (such as the risk for skin cancer and 
liver disease) differ with regard to patients with plaque-type 
psoriasis due to their past medical history, including previous 
exposure to UV phototherapy, methotrexate or other medica-
tions. At present, there is a lack of sufﬁ  cient long-term data 
about the safety of inﬂ  iximab in patients with plaque psoriasis. 
For the safety of this chimeric biologic, key points that must 
be included are infusion/injection reactions and infections, 
including rare but important opportunistic infections.
As for other foreign protein-derived treatments, the 
intravenous administration of inﬂ  iximab is also at risk of 
causing infusion reactions, which can be classiﬁ  ed as acute 
reactions, occurring during the infusion or in the ﬁ  rst 24 hours 
afterwards, or delayed reactions, occurring between 24 hours 
and 14 days after the infusion (for the most part after 5–7 
days).29 Acute infusion reactions are usually graded as mild, 
moderate or severe, based on patients’ signs and symptoms,29–
31 and appeared to be the most frequent reason for discontinu-
ation of therapy in clinical trials (2.8% discontinuation rate 
in all clinical trials). In the EXPRESS clinical trial, infusion 
reactions were observed in about 3% to 7% of infusions with 
inﬂ  iximab compared with 1% to 2% of infusions with pla-
cebo.24 Most infusion reactions were mild (ﬂ  ushing, dizziness, 
headache, sweating, palpitations or nausea) to moderate (chest 
tightness, shortness of breath, hypo/hypertension, raised tem-
perature or urticaria), whereas severe infusion reactions (a 
change in blood pressure of more than 40 mmHg, wheezing, 
stridor, severe fever with rigors) were rarely reported. Among 
935 patients in clinical trials, 3% had non-speciﬁ  c fever and 
chills, and less than 1% of infusions were serious, including 
anaphylaxis and hypotension.32 Acute infusion reactions to 
inﬂ  iximab often develop with symptoms suggestive of ana-
phylactic reactions (systemic reactions due to the massive 
IgE-mediated release of mast cell products, such as histamine, 
triptase or cytokines, also known as type I hypersensitivity 
reactions);33 however recent evidence seems to prove that 
most of the anaphylactic-like reactions to inﬂ  iximab are 
anaphylactoid rather than true type I hypersensitivity reac-
tions,29,30,34,35 being clinically similar to the latter but having 
a different pathogenesis (mast cells are directly degranulated 
and activated, without IgE playing any role). As for delayed 
infusion reactions to inﬂ  iximab, they clinical resemble mild 
serum sickness (rash, fever and polyarthralgias/polyarthritis), 
even if typical laboratory ﬁ  ndings have not been identiﬁ  ed.30,36 
Interestingly, the incidence of mild to moderate infusion 
reactions has been proven to be relevantly increased if case 
of inﬂ  iximab administration leading to the development of 
human antichimeric antibodies versus inﬂ  iximab, also known 
as ATI;24,29 ATI occurs in 7% to 61% of patients suffering 
from psoriasis, RA and Crohn’s disease;37 Baert et al38 showed 
in a retrospective cohort study that a high risk of infusion 
reactions can be predicted by ATI serum concentrations of 8 
μg/mL or higher. The risk of developing ATI appears to be 
linked to both the infusion schedule and the co-administration Clinical, Cosmetic and Investigational Dermatology 2009:2 32
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of immunosuppressants. Despite the lack of good comparative 
clinical studies, there is some evidence that the formation 
of ATI is less likely to develop by loading the inﬂ  iximab 
therapy with three infusions, respectively at weeks 0, 2 and 6, 
instead of only one initial infusion,36 and by maintenance 
treatment (an infusion every 8 weeks) instead of on-demand 
inﬂ  iximab administration.39 The combination of inﬂ  iximab 
and methotrexate seems to be particularly interesting; based 
on previous experiences in Crohn’s disease and RA,40–42 the 
combination with methotrexate, especially if the regimen 
is continued for more than 4 months, signiﬁ  cantly reduces 
the immunogenicity of inﬂ  iximab and, as a consequence, 
the risk of ATI formation and infusion reactions. However 
in this case the possibility of immunosuppression is higher. 
It is also important to emphasize that there is no solid 
evidence about the efﬁ  cacy of premedication (consisting 
of paracetamol, anthistamines or steroids given before the 
infusion) either in primary or secondary prophylaxis against 
infusion reactions,43–45 although it is routinely adminis-
tered for both purposes and it might lower the severity of 
a potential infusion reaction; consequently the additional 
beneﬁ  ts deriving from the routine premedication should be 
weighed against the chance of potential side-effects, even if 
small. In case of mild or moderate acute infusion reaction, it 
is recommended to slow down the infusion or even to interrupt 
it, to infuse physiologic saline, to treat with antihistamines 
and paracetamol, then to restart the inﬂ  iximab infusion at 
an initially reduced rate. A delayed infusion reaction should 
be treated by administrating antihistamines and, if indicated 
by the severity of the situation, steroids. Mild to moderate 
reactions should not induce the physician to interrupt the 
inﬂ  iximab treatment, whereas in case of serious reactions it 
is suggested that the pros and the cons of the therapy should 
be evaluated.
In order to reduce the risk of a new reaction, besides 
a stronger premedication, other available options are: 
1) modifying the dosage, 2) reducing the rate of the infusion 
in case of a previous acute reaction, 3) reducing the interval 
between infusions in case of a previous delayed reaction,29 
4) adding an immunosuppressant such as methotrexate, 
5) desensitizing procedure (an extreme solution which should 
be adopted only if inﬂ  iximab treatment is to be continued 
despite a severe reaction).38
Infections
As an immunosuppressant, inﬂ  iximab can reduce resistance 
to infection, because TNF is a pivotal cytokine in the host 
defense, especially against certain infective pathogens. 
Infections are the most common adverse events reported 
in literature related to TNF-α antagonists. There seems 
to be an increased risk associated with TNF antagonist 
treatment for severe and soft tissue infections, for bacterial 
intracellular infections, and for granulomatous infections.46 
Tuberculosis is the most frequent granulomatous infection 
occurring under anti-TNF-α treatment; TNF-α is essential 
for tubercular granuloma development and disease 
containment, so that TNF inhibition might lead to 
reactivation of latent tuberculosis infection (LTBI). 
Therefore, potential recipients of TNF antagonists should 
be rigorously screened for tuberculosis (TB), with a detailed 
medical history, questioning about potential TB exposure 
including recent travel assessment for symptoms such as 
cough and weight loss, puriﬁ  ed protein derivative (PPD) 
skin testing and a chest radiograph. In case of a positive 
PPD test associated with a negative chest X-ray, inﬂ  iximab 
could be administered in association with a concomitant 
antitubercular chemoprophylaxis (isoniazid prescribed for 
6–9 months).47 However, this clinical approach does not 
completely avert the chance of a tubercular reactivation.48 
Interferon assay (QFT-G), being highly speciﬁ  c and sensitive 
in diagnosing LTBI,49 should be employed in parallel with 
conventional procedures, assuming LTBI in case of a posi-
tive result of any of the aforementioned assays. For the same 
reason, before starting the inﬂ  iximab treatment every patient 
ought to be tested for hepatitis and HIV serologic markers. 
Besides the tubercular risk, other rare and/or opportunistic 
infections have been reported in association with inﬂ  iximab 
therapy, such as pulmonary actinomycosis,50 Listeria 
monocytogenes and Plasmodium falciparum sepsis,51,52 
latent visceral Leishmania reactivation,53 cryptococcal 
meningitis and life-threatening histoplasmosis.54,55 As with 
other immunosuppressive drugs, inﬂ  iximab should not 
be given to patients with active infections. The value of 
screening measures has been highlighted by the reduction 
of reported TB cases in patients receiving inﬂ  iximab after 
the regular adoption of educational programs and screening 
for TB, although the role of screening is more uncertain in 
relation to opportunistic pathogens’ prevention.46
Inﬂ  iximab, quality of life
and nail involvement
Psoriasis inﬂ  uences signiﬁ  cantly the health-related quality of 
life (HRQoL) issues, including the physical, psychological 
and social facets of the patient’s life.56,57 For this reason, as 
proved by different studies, the treatment with inﬂ  iximab 
is effective even on patient QoL. Feldman et al58 in the Clinical, Cosmetic and Investigational Dermatology 2009:2 33
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EXPRESS II study involving 835 patients with moderate-to 
severe plaque psoriasis, showed that inﬂ  iximab is associated 
with a dramatic improvement of disease severity (PASI) and 
HRQoL (Dermatology Life Quality Index, DLQI; 36-item 
Short-Form Health Survey, SF-36). In particular patients 
treated with inﬂ  iximab gained signiﬁ  cant improvements in 
both non-speciﬁ  c HRQoL (evaluated by SF-36, PCS and 
MCS) and disease-speciﬁ  c HRQoL (measured by DLQI), 
compared with placebo. Inﬂ  iximab signiﬁ  cantly improved 
HRQoL and related comorbidities such as depression and 
anxiety, underlying that a comprehensive assessment of treat-
ment efﬁ  cacy against psoriasis must include the evaluation 
not only of the severity of skin lesions but also of social and 
psychological morbidities.59
In this context 20% to 55% of patients with psoriasis 
suffer from nail psoriasis.60 Nail involvement (usually 
measured in clinical trials by the nail psoriasis severity 
index, NAPSI score) is a relevant source of distress due to its 
chronic course (characterized by ﬂ  are-ups and remissions), 
the localization of the lesions (affected ﬁ  ngernails are 
visible during the whole year, disﬁ  gured toenails torment 
female patients during summertime) and the predisposition 
to bacterial or mycotic infections in case of nail dystrophy; 
and the pain represents a serious obstacle to daily activities.61 
Nail psoriasis has a great impact on HRQoL, increasing 
the depression and anxiety scores among PsA.61 Moreover, 
many authors have found a relationship between nail dis-
ease and PsA:62–65 there is an increased prevalence of nail 
involvement among patients with PsA. Gladman et al66 
proposed that this feature is the only one clinically able to 
identify psoriatic patients prone to develop PsA in the near 
future. Since the extensor tendon enthesis forms an integral 
supporting structure for the nail,67 it has been hypothesized 
that the anatomical proximity could explain the association 
between distal interphalangeal involvement (DIP), enthe-
sopathy and nail dystrophy in PsA.68 In this way nail pso-
riasis could represent a pathogenetic connection between 
skin and joint involvement.69 However, this assumption 
has been denied by other clinical studies, which have failed 
to find a significant association between DIP and nail 
involvement;70,71 nevertheless, in patients without PsA, nail 
disease is associated with bone involvement of the distal 
phalange (valued as erosion and/or osteitis as seen by means 
of hands and feet X-ray), and the severities of these condi-
tions appear to be correlated.72
Therapy of psoriatic nails represents a challenge for 
dermatologists. In psoriatic patients with nail involvement, 
inﬂ  iximab proved to be effective in signiﬁ  cantly ameliorat-
ing the NAPSI score after three infusions, leading often to 
complete remission by the next one/two infusions.24,61,72 The 
efﬁ  cacy is directed against both matrix and nail bed signs, and 
no signiﬁ  cant difference has been detected between patients 
with or without PsA. In case of nail psoriasis, systemic 
therapy should be adopted only if there is extensive skin 
and/or joints involvement or if there is an extremely severe 
condition such as pustular psoriasis.73,74
Inﬂ  iximab and psoriatic arthritis
PsA is a chronic inﬂ  ammatory arthropathy characterized by 
different clinical forms of joint disease ranging from mild 
Figure 1 Complete clinical response of plaque type psoriasis with nail involvement after 3 infusions of inﬂ  iximab.Clinical, Cosmetic and Investigational Dermatology 2009:2 34
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synovitis to severe erosive arthritis. The latter occurs in 40% 
to 60% of PsA patients, showing a progressive course from 
the ﬁ  rst year of diagnosis.75,76
Inﬂ  iximab has been proved to be effective in the treatment 
of PsA. FDA and EMEA have approved its use in active 
and progressive PsA. In the placebo-controlled randomized 
trials relating to the efﬁ  cacy of inﬂ  iximab in PsA, achieve-
ment of the ACR20 was established as the primary end 
point. In order to achieve an ACR20 response, the following 
clinical and laboratory ﬁ  ndings were required: at least a 
20% reduction in the number of tender joint count, at least a 
20% reduction in the swollen joint count, and at least a 20% 
improvement in at least three of the following assessments: 
patient pain assessment, patient global assessment, physi-
cian global assessment, patient self-assessed disability, and 
acute phase reactants (C-reactive protein or erythrocyte 
sedimentation rate).77 In the phase II and phase III controlled 
clinical trials evaluating the administration of inﬂ  iximab in 
patients with PsA, the rate of inﬂ  iximab-treated patients 
achieving an ACR20 response after 12 to 16 weeks was 
signiﬁ  cantly higher than the rate in the placebo group; in 
the Inﬂ  iximab Multinational Psoriatic Arthritis Controlled 
Trial (IMPACT) and IMPACT 2 trials, 65.4% (IMPACT) 
and 58% (IMPACT 2) of patients with PsA receiving 
inﬂ  iximab (5 mg/kg at weeks 0, 2, and 6, then every 8 weeks, 
1 concomitant DMARD [IMPACT] or concomitant metho-
trexate [IMPACT2] allowed) achieved an ACR20 response 
at week 16 and at week 14, respectively (placebo, 10% 
[IMPACT] and 16% [IMPACT 2]).78,79 At the same time 
points, an ACR70 response was achieved by 15% and 28% 
of patients in the inﬂ  iximab-treated group (placebo, 0% and 
1%, respectively). Of note, the clinical response to inﬂ  iximab 
was sustained throughout a radiographic assessment showing 
the inhibition of the disease progression and the potential 
property of preventing irreversible joint impairment.80
The management of long-term 
treatment
Currently no deﬁ  nite guidelines are available with regard to 
the long-term management of inﬂ  iximab therapy. However 
this information is crucial because psoriasis a chronic disease 
and as a consequence speciﬁ  c treatments are likely to have 
to be continued for a long time. Despite the lack of well 
established data-based clinical investigations into the long-
term administration of inﬂ  iximab, a dermatology expert panel 
recently reached a consensus in this issue, explaining key 
decision points about long-term moderate-to-severe psoriasis 
management and long-term inﬂ  iximab therapy.81 In relation 
to the initial level of efﬁ  cacy, the consensus of the panel was 
that an improvement in symptoms should be at least 75%. 
After 12 weeks (induction period) of treatment, inﬂ  iximab 
should be continued as long as the patient has achieved at 
least PASI 50. If the patient fails to achieve PASI 50 after 6 
months, this may be considered a “non-response” and patients 
should be switched to another treatment.
During the long-term treatment with inﬂ  iximab, a slight 
decrease (10%–20%) in PASI score can be observed. This 
trend does not indicate that the therapy is not successful any 
more, as long as the absolute level of PASI and improvement 
in DLQI remain acceptable. Until the consensus statements 
are corroborated by robust clinical data, these recommenda-
tions provide at this time reliable guidelines about how to 
manage inﬂ  iximab treatment in the long term.
Costs
One of the main limitations to the use of inﬂ  iximab as well 
as other biologics as ﬁ  rst-line anti-psoriatic agents is their 
cost. For this reason in Europe, biologics can be prescribed 
only in patients unresponsive or with contraindication to 
conventional treatments.
The pharmaceutical total cost for inﬂ  iximab for moderate- 
to-severe psoriasis after 1 year is  15,162.64. A recent Italian 
study (unpublished) evaluating the cost-effectiveness of 
inﬂ  iximab compared with the others biologic agents for the 
treatment of psoriasis showed a higher efﬁ  cacy both in terms 
of PASI and DLQI scores of inﬂ  iximab when compared to 
efalizumab, adalimumab and etanercept.
Conclusions
This review demonstrated a high degree of clinical response 
to inﬂ  iximab in patients with moderate-to-severe plaque 
psoriasis. The results showed a rapid response in onset and 
persistence over time for the majority of patients, especially 
for those who received regular infusions of 5 mg/kg 
every 8 weeks. Improvement in PASI was paralleled by 
improvement in PGA score and QoL, as assessed by DLQI 
and SF-36 scores. This anti-TNF-α agent was shown to be 
effective in the treatment of nail psoriasis, although the latter 
alone cannot be considered an indication for inﬂ  iximab. If 
nail psoriasis is recognized as an early sign of joint involve-
ment, the current guidelines will be probably appropriately 
addressed.
Inﬂ  iximab has an encouraging safety proﬁ  le, especially as 
long as physicians are watchful in preventing and early diag-
nosing infections and infusion reactions. The long-term treat-
ment should be managed based on the sustained achievable Clinical, Cosmetic and Investigational Dermatology 2009:2 35
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efﬁ  cacy and on the speciﬁ  c demands of individual patients, 
although further clinical studies are needed to investigate 
this issue and to produce deﬁ  nite guidelines.
Expert opinion
At the University of Rome Tor Vergata, we have been using 
inﬂ  iximab for 7 years and we have treated more than 250 
patients. Inﬂ  iximab has been shown to have a rapid onset of 
action maintaining a sustained efﬁ  cacy for up to 4 to 5 years 
of continuous therapy in terms of PASI 75 and PASI 90. 
Temporary reductions in efﬁ  cacy have been observed after the 
6th year. When a loss of response to inﬂ  iximab is observed, 
we suggest: 1) waiting and monitoring the patient for the 
next two infusions; 2) if the patient shows a persistent loss 
of efﬁ  cacy, a drug such as methotrexate or ciclosporin could 
be combined for a short period until efﬁ  cacy is regained. In 
other cases reduction of the inﬂ  iximab infusion interval from 
8 to 6 weeks or 4 weeks can be considered.
In our daily practice the choice among inﬂ  iximab and 
other biologics is made according to patients and their 
disease features. Patients with signiﬁ  cant psychological 
involvement or with more severe disease are treated with 
inﬂ  iximab since this anti-TNF-α agent is characterized by a 
more rapid clinical response. In contrast patients preferring 
a subcutaneous and intermittent therapy are treated with the 
other anti-TNF-α agents.
To monitor drug safety and the risk of opportunistic 
infections, we suggest chest radiography once a year, the 
interferon assay for the increased risk of TB twice a year 
and blood exams at every infusion.
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